Recce Pharmaceuticals Advances with 93% Efficacy in Phase II and $15.8M Capital Raise

• Successful dosing of all 30 patients in Phase II trial of R327G for ABSSSI
• Positive Phase II data showing 93% primary efficacy endpoint met with no serious adverse events
• Japan Patent Office grants allowance for anti-infectives patent family, extending protection to 2041
• A$5 million placement and A$10.8 million entitlement offer launched to fund Phase III clinical trials